Startseite>>Signaling Pathways>> Others>> Lipases>>Arachidonoyl-1-thio-Glycerol

Arachidonoyl-1-thio-Glycerol (Synonyms: 1SArachidonoyl1mercapto2,3propanediol)

Katalog-Nr.GC42844

2-Arachidonoyl glycerol (2-AG) is an endogenous agonist of the central cannabinoid (CB1) receptor.

Products are for research use only. Not for human use. We do not sell to patients.

Arachidonoyl-1-thio-Glycerol Chemische Struktur

Cas No.: 1309664-54-7

Größe Preis Lagerbestand Menge
1mg
37,00 $
Auf Lager
5mg
170,00 $
Auf Lager
10mg
302,00 $
Auf Lager
25mg
659,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

2-Arachidonoyl glycerol (2-AG) is an endogenous agonist of the central cannabinoid (CB1) receptor. It is present at relatively high levels in the central nervous system and is the most abundant molecular species of monoacylglycerol found in rat brain. Monoacylglycerol lipase (MAGL) hydrolyzes 2-AG to arachidonic acid and glycerol, thereby terminating its biological actions. Arachidonoyl-1-thio-glycerol is a thioester substrate analog of 2-arachidonoyl glycerol that can be utilized for the measurement of MAGL activity. Hydrolysis of the thioester bond by MAGL generates a free thiol that reacts rapidly with the chromogenic reagent DTNB (Ellman's reagent) resulting a yellow product with an absorbance maximum at 412 nm.

Bewertungen

Review for Arachidonoyl-1-thio-Glycerol

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Arachidonoyl-1-thio-Glycerol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.